Asset
ZELICAPAVIR
ENANTA PHARMACEUTICALS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07482657 | phase2 | recruiting | 2026-07-09 | 2026-12-01 | Enanta Pharmaceuticals, Inc | A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus |
| NCT03384823 | phase1 | completed | 2017-12-07 | 2018-07-03 | Enanta Pharmaceuticals, Inc | A Study of EDP-938 in Healthy Subjects |
| NCT05568706 | phase2 | completed | 2022-11-29 | 2025-06-23 | Enanta Pharmaceuticals, Inc | A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications. |
| NCT04196101 | phase2 | completed | 2020-01-22 | 2022-01-04 | Enanta Pharmaceuticals, Inc | A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects |
| NCT04816721 | phase2 | completed | 2022-04-26 | 2024-08-19 | Enanta Pharmaceuticals, Inc | A Study to Evaluate EDP 938 Regimens in Children With RSV |
FDA applications (0)
This company has no applications containing this asset.